- Senate passes Drug Quality and Security Act
- FDA approves Plan B One-Step OTC switch
- Facing pharmacy trends for the remainder of the year
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
LONDON — Drug maker GlaxoSmithKline is seeking Food and Drug Administration approval for a new treatment for Type 2 diabetes, the drug maker said.
GSK announced the submission to the FDA of a regulatory approval application for albiglutide. The drug is not approved in any market yet, and the company plans to also seek approval in the European Union this year.
GSK assumed control of albiglutide with its $3.6 billion acquisition of Human Genome Sciences, announced last July.